Y-90 SIRT for Unresectable HCC Larger Than 7cm
Condition(s) studied
Investigational drug(s) / intervention(s)
SIRT: The patients will receive 1-2 sessions of SIRT.
Study summary
This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy. The primary endpoint of the study is objective reponse rate (ORR) as assessed by mRECIST. Secondary endpoints were: objective response rate (ORR) as assessed by RECIST 1.1, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DOR), overall survival (OS), and safety (incidence and severity of adverse events).
Eligibility
Primary outcome measure(s)
- Objective response rate (ORR) per mRECIST — 3 years
The proportion of patients with the best response of complete response (CR) or partial response (PR) according to mRECIST
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | Not Yet Recruiting |
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | Recruiting |
More Second Affiliated Hospital of Guangzhou Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06707233 on ClinicalTrials.gov ↗ ← All trials in China